LABORATORY RESEARCH Toca-1 Is Suppressed by p53 to Limit Breast Cancer Cell Invasion and Tumor Metastasis Researchers observed that breast cancer cell lines with mutant p53 have high levels of Toca-1 compared to those with WT p53. Stabilization of WT p53 led to further reduction in Toca-1 mRNA and protein levels in normal breast epithelial cells and breast cancer cells. [Breast Cancer Res] Abstract | Full Article MicroRNA-574-3p, Identified by MicroRNA Library-Based Functional Screening, Modulates Tamoxifen Response in Breast Cancer To identify tamoxifen response-related microRNAs (miRNAs) in breast cancer, MCF-7 cells infected with a lentiviral miRNA library were treated with 4-hydroxytamoxifen or vehicle for four weeks, and the amounts of individual miRNA precursors that had integrated into the genome were evaluated by microarray. [Sci Rep] Full Article Disulfiram-Induced Cytotoxicity and Endo-Lysosomal Sequestration of Zinc in Breast Cancer Cells Few studies have investigated zinc effects on disulfiram action, despite it having high affinity for this metal. Investigators studied the cytotoxic effects of disulfiram in breast cancer cells, and its relationship with both intra and extracellular zinc. [Biochem Pharmacol] Abstract HET0016, a Selective Inhibitor of 20-HETE Synthesis, Decreases Pro-Angiogenic Factors and Inhibits Growth of Triple Negative Breast Cancer in Mice A selective inhibitor of 20-HETE synthesis, HET0016, has been reported to inhibit angiogenesis. HET0016 effects were analyzed on MDA-MB-231 derived breast cancer in mouse and in vitro cell line. [PLoS One] Full Article Differentially Expressed Proteins in Human MCF-7 Breast Cancer Cells Sensitive and Resistant to Paclitaxel In order to detect proteins potentially involved in the mechanism of resistance to taxanes, researchers assessed differences in protein expression in MCF-7 breast cancer cells that are sensitive to paclitaxel and in the same cells with acquired resistance to paclitaxel. [Exp Cell Res] Abstract Caveolin-1 Mediates Inflammatory Breast Cancer Cell Invasion via the Akt1 Pathway and RhoC GTPase Using a reliable inflammatory breast cancer (IBC) cell line, scientists set out to determine if caveolin-1 expression affects RhoC-mediated IBC invasion. IBC cell invasion is significantly decreased when caveolin-1 is down regulated. [J Cell Biochem] Abstract Role of EHD2 in Migration and Invasion of Human Breast Cancer Cells The authors investigated the role of eps15 homology domain-containing 2 (EHD2) in breast cancer migration and invasion by wound healing assay and trans-well invasion assays. Overexpression of EHD2 suppressed, while elimination of EHD2 promoted, the migration and invasion of breast cancer cells. [Tumor Biol] Abstract Upregulation of Acetylcholinesterase Mediated by p53 Contributes to Cisplatin-Induced Apoptosis in Human Breast Cancer Cell The regulation of acetylcholinesterase (AChE) expression during apoptosis induced by cisplatin, a current used anticancer drug, was investigated in human breast cancer cell line MCF-7. [J Cancer] Full Article CLINICAL RESEARCH Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer Investigators performed an uncontrolled, single-group, multicenter, investigator-initiated study of adjuvant paclitaxel and trastuzumab in 406 patients with tumors measuring up to 3 cm in greatest dimension. Patients received weekly treatment with paclitaxel and trastuzumab for 12 weeks, followed by nine months of trastuzumab monotherapy. [New Engl J Med] Abstract | Press Release PIK3CA Mutations Are Associated with Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer Researchers investigated whether mutations in the gene encoding the phosphatidylinositol 3-kinase catalytic subunit (PIK3CA) correlates with response to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in patients with breast cancer. [J Clin Oncol] Abstract | Press Release | Editorial Phase II, Multicenter, Open-Label, Randomized Study of YM155 plus Docetaxel as First-Line Treatment in Patients with HER2-Negative Metastatic Breast Cancer Researchers assessed the efficacy and tolerability of YM155, a survivin suppressor, in combination with docetaxel, compared with docetaxel alone in patients with HER2-negative metastatic breast cancer. [Breast Cancer Res Treat] Full Article |